SALT LAKE CITY, April 8, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (Nasdaq:PRSN) (Perseon or the Company), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that the company received clearance from the U.S. Food and Drug Administration (FDA) to market the MicroThermX® Microwave Ablation System (MicroThermX) for the specific indication of laparoscopic ablation procedures using image guidance.
"This new indication increases the type of cases that our technology will be used for and the opportunity to expand the use of MicroThermX in surgical oncology," said Clint Carnell, CEO of Perseon. "This moves us closer to achieving our clinical initiatives to benefit patients, physicians, and the healthcare system worldwide."
Perseon Corporation, formerly BSD Medical Corporation, is a life sciences company that develops, manufactures, markets and services groundbreaking medical systems to treat cancer using heat therapy. Perseon's MicroThermX® microwave ablation system employs precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property and distributes its products in the United States, Europe and Asia.
Statements contained in this press release that are not historical facts, including statements relating to our intent to divest our hyperthermia business in Spring 2015, focus on microwave ablation to create stockholder value, comply with Nasdaq continued listing requirements, generate capital from a transaction related to our building and pursue other strategic plans are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties, including the risk that for a variety of reasons we may not be able to execute on our strategic plans, and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.
CONTACT: Tricia Ross Financial Profiles 310-622-8226 firstname.lastname@example.org